Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder

Phase 4CompletedNCT01195363

The University of Texas Health Science Center at San Antonio28 enrolled

Overview

To assess the acute and long-term bimodal efficacy of QTP, as an adjunct to ongoing treatment with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any combination of the three thereof, in a group of patients with an index episode of a mixed state in BD.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Bipolar Disorder

Interventions

quetiapine SRDRUG

quetiapine SR, dose range 200-600mg, each night QHS for 6mos

quetiapine sr placeboDRUG

quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female; * Age 18 years and older * Patients on: * Li at a stable dose for 4 weeks or longer, and a serum level at screening of 0.5 mEq/l OR * DIV dose for 4 weeks or longer, and a serum level at screening of 45 g/ml OR * LAM (dosage/day ≥100mg) at a stable dose for 4 weeks or longer OR * Any combination 3a, 3b, or 3c * Patients meeting DSM-IV TR diagnosis of bipolar disorder, I or II, as assessed using the MINI, (Sheehan et al., 1998) PLUS any ONE of criteria 5 or 6 or 7 * Patients meeting DSM-IV TR diagnostic criteria for a mixed manic episode with Young Mania Rating Scale (YMRS) score\>/=14 and Montgomery Asberg Depression Rating Scale (MADRS) score\>/=14 * Patients meeting the criteria for a manic/hypomanic episode for at least 2 days with the simultaneous presence of Young Mania Rating Scale (YMRS) score\>/=14 PLUS Montgomery Asberg Depression Rating Scale (MADRS) score\>/=14 ; * Patients meeting DSM-IV TR diagnostic criteria for a major depressive episode with the simultaneous presence of MADRS score\>/=14 PLUS meeting the criteria for a manic/hypomanic episode for at least 2 days with the simultaneous presence of Young Mania Rating Scale (YMRS) score\>/=14 Exclusion Criteria: * Patients with a current Axis I diagnosis of schizophrenia, schizophreniform disorder, schizotypal disorder, bipolar disorder with psychotic subtype, drug induced mania or AIDS induced mania * Women with a positive pregnancy test or who are lactating * Women of child-bearing potential who are not practicing a clinically accepted method of contraception * Patients with general medical conditions that contraindicate psychoactive medications or uncontrolled medical disorder or central nervous system diseases. * Patients whose clinical status requires inpatient or day hospital treatment * History of severe side effects associated with therapeutic doses of Li, DIV, LAM * Alcohol or drug dependent at time of enrollment * Suicidal at time of enrollment. * Current or previous exposure to QTP

Locations (1)

The University of Texas Health Science Center at San Antonio

San Antonio, Texas, United States

Outcomes

Primary Outcomes

Number of Patients Whose Mood Improved According to MADRS and YMRS Scale Scores.

The primary outcome measure was assessed by 50% reduction in: 1. depression scores on the Montgomery Asberg Depression Rating Scale (MADRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms 2. mania scores on the Young Mania Rating Scale (YMRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms.

Time frame: Baseline visit to week 24

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.